Back to today’s briefing

Story perspectives

Study Reveals GLP-1 Drugs Triple Vision Loss Risk

10/7/2025

50 4

Summary

Story summary

A 2025 study links glucagon-like peptide-1 (GLP-1) receptor agonists to a threefold risk of sudden vision loss.
Serious side effects include pancreatitis and thyroid tumors, with about 10,000 reactions since 2018.
A 2024 study finds up to 60% of Liraglutide weight loss may be lean muscle.
Discontinuing GLP-1 receptor agonists often leads to regaining two-thirds of lost weight within a year.

1 of 1

Story summary

A 2025 study links glucagon-like peptide-1 (GLP-1) receptor agonists to a threefold risk of sudden vision loss.
Serious side effects include pancreatitis and thyroid tumors, with about 10,000 reactions since 2018.
A 2024 study finds up to 60% of Liraglutide weight loss may be lean muscle.
Discontinuing GLP-1 receptor agonists often leads to regaining two-thirds of lost weight within a year.